Fed Governor Adriana Kugler to resign
On Wednesday, Truist Securities adjusted their financial outlook for Intuitive Surgical (NASDAQ:ISRG), reducing the price target to $590 from $605, while retaining a Buy rating on the company’s shares. Currently trading at $513.35, the company commands a substantial market capitalization of $184.6 billion. The revision follows Intuitive Surgical’s recent earnings report, which exceeded expectations for both revenue and earnings per share (EPS) due to increased procedural volumes, with revenue growing 17.24% year-over-year. However, the company’s EPS forecast was tempered due to the anticipated impact of tariffs. According to InvestingPro analysis, the stock is currently trading above its Fair Value, with 13 key insights available to subscribers.
In his commentary, the Truist Securities analyst acknowledged the positive results from the first quarter, highlighting the revenue and EPS beat as a result of a higher number of procedures. The company maintains a healthy gross profit margin of 67.46% and operates with minimal debt, as revealed in the comprehensive InvestingPro Research Report. The analyst pointed out that although the gross margin is expected to be affected by approximately 170 basis points due to tariffs, this was in line with expectations, assuming no mitigations. Moreover, the analyst suggested that the actual impact might be less severe than anticipated, referencing President Trump’s remarks indicating that the China levy could be less than the 145% assumed in the guidance.
Despite a quarter-over-quarter decline, the performance of the company’s Da Vinci (EPA:SGEF) systems (D5) met expectations. The analyst noted that while investors might scrutinize this aspect, the management’s outlook for U.S. capital spending was more optimistic than anticipated, with normal seasonal trends emphasized.
In conclusion, the analyst at Truist Securities expressed a long-term bullish stance on Intuitive Surgical, recommending the stock as a potential addition for long-term investors, particularly during macroeconomic pullbacks. The company’s latest financial performance, despite the challenges posed by tariffs and global economic uncertainty, was seen as a positive sign by Truist Securities.
In other recent news, Intuitive Surgical reported first-quarter earnings for 2025 that exceeded expectations, with revenue reaching $2.253 billion and an adjusted earnings per share (EPS) of $1.81. This strong performance led to an increase in the company’s full-year procedure growth guidance to 15-17%. However, the company has revised its gross margin forecast for fiscal year 2025 to 65-66.5%, citing tariffs as a significant factor. Analysts have responded by adjusting their price targets for Intuitive Surgical. Piper Sandler lowered the target to $575, Raymond (NSE:RYMD) James adjusted it to $592, Bernstein set it at $675, Leerink Partners revised it to $539, and BTIG changed it to $542, with most maintaining positive ratings. Despite the tariff-related challenges, analysts like those from Raymond James and Bernstein remain optimistic about the company’s long-term growth potential. The introduction of the Da Vinci 5 system and strong procedure growth are seen as key factors supporting Intuitive Surgical’s market position. Overall, while some margin pressure is expected, the company’s prospects remain favorable according to these recent analyses.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.